GlassScriptPhysician profile
Lawrence Kashat
NPI 1205290137
$987.29
in general payments reported to CMS, 2019-2025
12 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $35.00 · 2024: $329 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649 · Debt Forgiveness: $15.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.07 |
| Debt Forgiveness | $15.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $221.28 | 2024-2025 | Nucala |
| Stryker Corporation | $204.18 | 2021 | |
| Genzyme Corporation | $164.14 | 2024-2025 | |
| Medtronic, INC. | $118.14 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $59.44 | 2024-2025 | Dupixent |
| Integra Lifesciences Corporation | $57.62 | 2024 | Integra, Inspira Air, Acclarent Aera |
| Kerecis Limited | $45.00 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Inspire Medical Systems, INC. | $41.00 | 2024 | Inspire |
| Convatec INC. | $24.13 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $18.78 | 2025 | Neffy |
| Paratek Pharmaceuticals, INC. | $17.68 | 2025 | Xhance |
| Olympus America INC. | $15.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kashat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.